Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare ConferenceGlobeNewsWire • 05/08/24
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial ResultsGlobeNewsWire • 05/07/24
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 05/01/24
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?Zacks Investment Research • 03/28/24
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewsWire • 03/26/24
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing DrugInvestors Business Daily • 02/27/24
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated MilestonesGlobeNewsWire • 02/27/24
Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to DeclineZacks Investment Research • 02/20/24
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewsWire • 02/05/24
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall StreetThe Motley Fool • 01/16/24
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated MilestonesGlobeNewsWire • 01/08/24
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/02/24